Physician profile

Derek J Luney

Cardiovascular Disease · Conover, NC

NPI 1679535363

$2,036.95

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $432.36 2019-2022
Amgen INC. $409.86 2019-2022
Novartis Pharmaceuticals Corporation $167.24 2019-2020
Astrazeneca Pharmaceuticals LP $126.22 2019-2022
Pfizer INC. $76.84 2021-2022
Sanofi-Aventis U.S. LLC $75.84 2019-2020
Chiesi USA, INC. $75.79 2019-2020
Abbott Laboratories $70.53 2020-2022
Boehringer Ingelheim Pharmaceuticals, INC. $67.25 2019-2022
Medtronic Vascular, INC. $60.43 2019
Amarin Pharma, INC. $57.11 2019-2020
Impulse Dynamics (USA) INC. $50.93 2021
Portola Pharmaceuticals, LLC $46.94 2019
Medtronic, INC. $44.06 2022
E.R. Squibb & Sons, L.L.C. $35.63 2019-2022
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Arbor Pharmaceuticals, INC. $35.61 2019
Astellas Pharma US INC $33.27 2019-2020
Otsuka America Pharmaceutical, INC. $31.64 2019
Irhythm Technologies, INC. $30.54 2019
Bardy Diagnostics, INC. $26.00 2019
Regeneron Healthcare Solutions, INC. $25.91 2019
Edwards Lifesciences Corporation $23.24 2019
Nuwellis, INC. $18.34 2019
Novo Nordisk INC $15.37 2022

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Derek J Luney

$2,036.95

in general payments reported 2019-2025

Years
2019-2022
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/303051/derek-j-luney

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.